Risk factors and survival of patients infected with carbapenem-resistant Klebsiella pneumoniae in a KPC endemic setting: a case-control and cohort study

Table 1 Characteristics of K. pneumoniae infections according susceptibility to carbapenems

Characteristics	Carbapenem-susceptible K. pneumoniae n = 289		Carbapenem-resistant K. pneumoniae n = 49		Total K. pneumoniae infections n = 338
Characteristics	n	%	n	%	n	%
Site of infection
Urinary tract infection (UTI)	82	28.37	13	26.53	95	28.11
Intra-abdominal infection	67	23.18	6	12.24	73	21.60
Surgical site infection	24	8.30	8	16.33	32	9.47
Bacteriemia	25	8.65	5	10.20	30	8.88
Catheter associated UTI	19	6.57	6	12.24	25	7.40
Pneumonia	19	6.57	3	6.12	22	6.51
Skin and soft tissue infections	18	6.23	2	4.08	20	5.92
Empirical treatment	262	90.66	45	91.84	307	90.83
Piperacillin/Tazobactam	169	58.48	21	42.86	190	56.21
Meropenem	59	20.42	21	42.86	80	23.67
Targeted treatment	270	93.43	39	79.59	309	91.42
Meropenem	125	43.25	30	61.22	155	45.86
Ciprofloxacin	49	16.96	4	8.16	53	15.68
Tigecycline	2	0.69	18	36.73	20	5.92
Colistin	0	0.00	10	20.41	10	2.96
Combined therapy	45	15.57	33	67.35	78	23.08
Surgical treatment	89	30.80	11	22.45	100	29.59
Hospital length stay (median, IQR)	18	(10–33)	26	(13–42)	19	(10–34)
30-day mortality (all-causes)	46	15.92	16	32.65	62	18.34

ISSN: 1471-2334